Media Cover-Up, Public Left in the Dark About Adult Stem Cell Superiority

It is almost definite that a presidential veto will obstruct the democratic controlled house and their recent effort to drive embryonic stem-cell research forward by expanding federal funding. The decision to boost funding won by a 253-174 vote, but fell under the 290 required to take precedence over any potential, and in this case expected, executive branch intervention.

Proponents of the bill say a veto would obstruct scientific efforts that could guide the way to prospective breakthroughs for the treatment of many diseases. But contrary to what many have been led to believe, that is not the case.

Adult stem cells, an ethical alternative to those that are derived from embryos, have proven themselves to be more effective thus far and have accomplished astonishing breakthroughs far beyond anything managed by their embryonic counterparts.

Almost 1,300 clinical trials are presently underway involving adult stem cells, and they are responsible for the treatment and cures for more than 70 diseases. A wider assortment of mature stem cells can be created using adult stem cells as science persistently proves. The January issue of Nature Biotechnology highlighted perhaps the most promising of these results.

Stem cells derived from the amniotic fluid that fills sacs surrounding the fetus emerged as an equal rival to embryonic stem cells. While preserving the imperative advantage of verified success over embryonic stem cells, they are also equivalent in terms of versatility compared to embryo derived cells. The discovery was reported by Anthony who is the director of the Institute for Regenerative Medicine at Wake Forest University School of Medicine.

Since there are no realistic applications for embryonic stem cells at the moment, those on the hunt for more embryonic stem cell funding from taxpayer dollars have felt distraught with the discovery. At least 10 years stand in the way of approved embryonic stem cell treatments according to researchers, and not even one single clinical trial has been performed using embryo derived cells thus far.

An advantage once held by embryonic cells was their capacity to replicate. Outside the body, adult stem cells cannot be multiplied for extended periods of time, where embryonic cells can expand indefinitely. However, with the ability to double every 36 hours, amniotic stem cells grow just as rapidly as embryonic cells. Without any indication of slowing, they have now been expanding the same amniotic stem cell line for two years at Wake Forest University.

Perhaps, one advantage still holds true for embryonic stem cells, and that is their potential to possibly develop into all 220 varieties of human cells. They can differentiate into all three subtypes of cells, or